Physician profile
Austin Tsai
NPI 1235225756
$2,618.12
in general payments reported to CMS, 2019-2025
31 companies · $1,078 in 2025
The $1,078 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $535 · 2020: $73.89 · 2021: $71.02 · 2022: $43.38 · 2023: $426 · 2024: $391 · 2025: $1,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,895.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,894.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $311.65 | 2019-2025 | |
| Lilly USA, LLC | $289.12 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $236.30 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $155.54 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $151.62 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $142.44 | 2023-2025 | Vraylar, Ubrelvy, Qulipta |
| Shield Therapeutics INC | $133.90 | 2023-2025 | Accrufer |
| Amgen INC. | $117.96 | 2019-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $94.78 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $91.52 | 2025 | Caplyta |
| Paragon 28, INC. | $71.02 | 2021 | |
| Novartis Pharmaceuticals Corporation | $67.46 | 2019-2024 | |
| Madrigal Pharmaceuticals | $60.79 | 2025 | Rezdiffra |
| Teva Pharmaceuticals USA, INC. | $60.51 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.12 | 2019-2025 | Xifaxan |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.99 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $56.16 | 2019-2025 | Veozah |
| Sumitomo Pharma America, INC. | $54.21 | 2024-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $52.88 | 2019-2020 | |
| Glaxosmithkline, LLC. | $51.99 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Phathom Pharmaceuticals, INC. | $46.54 | 2024-2025 | Voquezna |
| Axsome Therapeutics, INC. | $42.03 | 2023-2025 | Auvelity |
| Gilead Sciences, INC. | $40.38 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.29 | 2023-2024 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $30.26 | 2019-2025 | Farxiga |
| Dexcom, INC. | $23.42 | 2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $20.68 | 2025 | Korlym |
| Janssen Pharmaceuticals, INC | $19.56 | 2025 | Spravato |
| Neurocrine Biosciences, INC. | $19.01 | 2025 | |
| Ibsa Pharma INC. | $14.88 | 2020 | |
| Genentech USA, INC. | $11.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Austin Tsai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.